Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 8Uveal Melanoma 2Neoplasm Metastasis 2Skin Neoplasms 1Neoplasms 1

Interventions

pembrolizumab 40Nivolumab 18trametinib 13Cyclophosphamide 13dabrafenib 11Vemurafenib 10Interleukin-2 10Ipilimumab 9fludarabine 7Docetaxel 7fludarabine phosphate 6cemiplimab 6Paclitaxel 6Cisplatin 6Carboplatin 6atezolizumab 5Radiotherapy 5Drug Therapy 5Dacarbazine 5Blood Specimen Collection 5Biopsy 5poly ICLC 4binimetinib 4Therapeutics 4Psychiatric Rehabilitation 4sotigalimab 3montanide ISA 51 3encorafenib 3cobimetinib 3budigalimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × gp100 Melanoma Antigen × Dermatologic × Clear all
NCT00960752 2021-08-13

Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist

M.D. Anderson Cancer Center

Phase 2 Completed
47 enrolled 9 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡